Neurogene Inc. Files 8-K on Nov 12, 2025

Ticker: NGNE · Form: 8-K · Filed: Nov 12, 2025 · CIK: 1404644

Sentiment: neutral

Topics: 8-K, SEC Filing, Corporate Update

TL;DR

NGNE filed an 8-K today, Nov 12, 2025. Big news incoming.

AI Summary

Neurogene Inc. filed an 8-K on November 12, 2025, reporting on events that occurred on the same date. The filing is a current report under the Securities Exchange Act of 1934, indicating significant corporate updates. Neurogene Inc. is a Delaware-incorporated company operating in the Pharmaceutical Preparations sector.

Why It Matters

This 8-K filing signifies that Neurogene Inc. has made a material event disclosure to the SEC, which could impact investors' understanding of the company's current status and future prospects.

Risk Assessment

Risk Level: medium — 8-K filings often contain material information that can lead to significant stock price movements, requiring careful investor attention.

Key Numbers

Key Players & Entities

FAQ

What specific event(s) triggered this 8-K filing on November 12, 2025?

The filing is a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, indicating a material event has occurred, but the specific details are not provided in this header information.

What is Neurogene Inc.'s primary industry?

Neurogene Inc. is classified under the Pharmaceutical Preparations industry, with SIC code 2834.

When did Neurogene Inc. change its name from Neoleukin Therapeutics, Inc.?

The date of the name change from Neoleukin Therapeutics, Inc. was August 12, 2019.

What is the principal executive office address for Neurogene Inc.?

The principal executive offices are located at 535 W 24th Street, 5th Floor, New York, NY 10011.

What is the company's fiscal year end?

The company's fiscal year ends on December 31.

Filing Stats: 599 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2025-11-12 17:11:44

Key Financial Figures

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure On November 12, 2025, Neurogene Inc. (the "Company") issued a press release announcing positive, updated interim clinical data in the pediatric cohort (ages 4-10 cohort) from its ongoing Phase 1/2 trial evaluating NGN-401 gene therapy for the treatment of females with Rett syndrome. A copy of the press release announcing such results is attached as Exhibit 99.1 to this Current Report on Form 8-K. On November 12, 2025, the Company also made available on its website a corporate presentation regarding the clinical data described in the press release referenced above. A copy of the presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K. The information in this Item 7.01 and Exhibits 99.1 and 99.2 attached hereto are being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information or Exhibits 99.1 and 99.2 be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference to such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release dated November 12, 2025 99.2 Corporate Presentation (November 12, 2025) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. NEUROGENE INC. Date: November 12, 2025 By: /s/ Christine Mikail Name: Christine Mikail Title: President, Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing